Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).

NCT06737354 is registered in ClinicalTrials.gov with InnoVec Biotherapeutics Inc. as lead sponsor.

NCT NCT06737354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06737354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Lead sponsor
InnoVec Biotherapeutics Inc.
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
April 22, 2025
Completion date
December 31, 2031
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

namd